References
1. Kutyrev V.V., Popova A.Yu., Smolensky V.Yu. et al. Epidemiological features of the novel coronavirus infection (COVID-19). Message 1: Models for the implementation of preventive and anti-epidemic measures. Prob-lemy osobo opasnykh infektsiy [Problems of Particularly Dangerous Infections]. 2020; (1): 6-13. (in Russian)
2. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. Lancet. 2020; 395 (10 223): 497506. DOI: DOI: https://doi.org/10.1016/S0140-6736(20)30183-5
3. Malinnikova E.Yu. New coronavirus infection. Today’s look at the 21st century pandemic. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2020; 9 [2 (33)]: 18-32. (in Russian)
4. Natale A., Ghio D., Tarchi D., Goujon A., et al. COVID-19 cases and case fatality rate by age. In: Knowledge for Policy. 2020: 1-18.
5. Korostovtseva L.S., Rotar O.P., Konradi A.O. COVID-19: what are the risks of hypertensive patients? Arterial’naya gipertenziya [Arterial Hypertension]. 2020; 26 (2): 124-32. (in Russian)
6. Pradhan A., Olsson P Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differ. 2020; 11 (1): 1-11. DOI: https://doi.org/10.1186/s13293-020-00330-7
7. Scully E., Haverfield J., Ursin R., Tannenbaum C., Klein S. Considering how biological sex impacts immune responses and COVID-19 outcomes. J Nat Rev Immunol. 2020; 20: 1-6. DOI: https://doi.org/10.1038/s41577-020-0348-8
8. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054-62. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3
9. Lian J., Jin X., Hao S., et al. Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) outside Wuhan. Clin Infect Dis. 2020; 71 (15): 740- 7. DOI: https://doi.org/10.1093/cid/ciaa242
10. Chen T., Wu D., Chen H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; March 26: 1-14. DOI: https://doi.org/10.1136/bmj.m1091
11. Gambaryan M.G., Drapkina O.M. Tobacco smoking and COVID-19: an old enemy in a new guise. Review of current scientific literature. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2020; 19 (3): 331-8. (in Russian)
12. Mareev Yu.V., Mareev V.Yu. Role of age, comorbidity and reninan-giotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers. Kardiologiya [Cardiology]. 2020; 60 (4): 4-9. (in Russian)
13. Popkin B., Du S., Green W., et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes Rev. 2020; 21 (11): 1-17. DOI: https://doi.org/10.1111/obr.13128
14. Dietz W., Santos-Burgoa C. Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring). 2020; 28 (6): 1005. DOI: https://doi.org/10.1002/oby.22818
15. Cai Q., Chen F., Wang T., et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care. 2020; 43 (7): 1392-8. DOI: https://doi.org/10.2337/dc20-0576
16. Zaytsev A.A., Golukhova E.Z., Mamalyga M.L., Kryukov E.V., et al. Effectiveness of pulse methylprednisolone therapy in COVID-19 patients. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya [Clinical Microbiology and Antimicrobial Chemotherapy]. 2020; 22 (2): 88-91. DOI: https://doi.org/10.36488/cmac.2020.2.88-91 (in Russian)
17. Guan W., Ni Z., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382 (18): 1708-20. DOI: https://doi.org/10.1056/NEJMoa2002032
18. Lawrence H., Hunter A., Murray R., Lim W., McKeever T. Cigarette smoking and the occurrence of influenza - systematic review. J Infect. 2019; 79 (5): 401-6. DOI: https://doi.org/10.1016/jjinf.2019.08.014
19. Liu W., Tao Z., Wang L., et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. 2020; 133 (9): 1032-8. DOI: https://doi.org/10.1097/CM9.0000000000000775.
20. Zhao J., Yang Y., Huang H., et al. Relationship between the ABO Blood Group and the COVID-19 susceptibility. medRxiv. 2020; March 27: 1-18. DOI: https://doi.org/10.1101/2020.03.11.20031096
21. Pourali F., Afshari M., Alizadeh-Navaei R., et al. Relationship between blood group and risk of infection and death in COVID-19: a live metaanalysis. medRxiv. 2020; June 8: 1-14. DOI: https://doi.org/10.1101/2020.06.07.20124610
22. Reid M., Mohandas N. Red blood cell blood group antigens: structure and function. Semin Hematol. 2004; 41 (2): 93-117. DOI: https://doi.org/10.1053/j.seminhematol.2004.01.001
23. Poschmann A., Fischer K., Seidl S., et al. ABH receptors and red cell survival in a «Bombay» blood: immunofluorescence studies by phytohemagglutinins and helix agglutinins. Vox Sang. 1974; 27 (4): 338-46. DOI: https://doi.org/10.1111/j.1423-0410.1974.tb02426.x
24. Tiongco R., Paragas N., Dominguez M. ABO blood group antigens may be associated with increased susceptibility to schistosomiasis: a systematic review and meta-analysis. J Helminthol. 2020; 94: е21. DOI: https://doi.org/10.1017/S0022149X18001116
25. Guillon P., Clement M., Sebille V., et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology. 2008; 18 (12): 1085-93. DOI: https://doi.org/10.1093/glycob/cwn093
26. Batool Z., Durrani S., Tariq S. Association of ABO and Rh blood group types to hepatitis B, hepatitis C, HIV and Syphillis infection, a five year’ experience in healthy blood donors in a tertiary care hospital. J Ayub Med Coll Abbottabad. 2017; 29 (1): 90-2.
27. Notari A., Torrieri G. COVID-19 transmission risk factors. medRxiv. 2020; May 7: 1-42. DOI: https://doi.org/10.1101/2020.05.08.20095083
28. Yang J., Koh H., Moon S., et al. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. J Allergy Clin Immunol. 2020; 146 (4): 790-8. DOI: https://doi.org/10.1016/jjaci.2020.08.008
29. Lopatin A.S., Chuchueva N.D. Epidemiology of allergic rhinitis in Russia and in the world. Rossiyskiy allergologicheskiy zhurnal [Russian Al-lergological Journal]. 2013; (2): 3-11. (in Russian)
30. Goren A., McCoy J., Wambier C., et al. What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. Dermatol Ther. 2020; March 8: 1-2. DOI: https://doi.org/10.1111/dth.13365.
31. Wambier C., Vano-Galvan S., McCoy J., et al. Androgenetic alopecia present in the majority of hospitalized with COVID-19 patients - the «Gabrin sign». J Am Acad Dermatol. 2020; 83 (2): 680-2. DOI: https://doi.org/10.1016/j.jaad.2020.05.079
32. Wambier C., McCoy J., Goren A. Male balding as a major risk factor for severe COVID-19: a possible role for targeting androgens and transmembrane protease serine 2 to protect vulnerable individuals. J Am Acad Dermatol. 2020; 83 (6): e400-2. DOI: https://doi.org/10.1016/j.jaad.2020.09.015
33. Moradi F., Enjezab B., Ghadiri-Anari A. The role of androgens in COVID-19. Diabetes Metab Syndr Clin Res Rev. 2020; 14 (6): 2003-6. DOI: https://doi.org/10.1016/j.dsx.2020.10.014
34. Renieri A., Benetti E., Tita R., et al. ACE2 variants underlie interindividual variability and susceptibility to COVID-19 in Italian. medRxiv. 2020; June 2: 1-28. DOI: https://doi.org/10.1101/2020.04.03.20047977
35. Saad-Roy M., Wagner C., Baker R., et al. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. Science. 2020; 370 (6518): 811-8. DOI: https://doi.org/10.1126/science.abd7343